Clinical Edge Journal Scan

RA causally associated with ischemic heart disease and myocardial infarction


 

Key clinical point: Rheumatoid arthritis (RA) is associated with a significant increase in the risk for ischemic heart disease (IHD) and myocardial infarction (MI), and managing RA activity may reduce the risk for cardiovascular diseases.

Major finding: RA is significantly associated with an increased risk for IHD (odds ratio [OR] 1.0006; P = .001551915) and MI (OR 1.0458; P = .001636), but not arrhythmia and atrial fibrillation.

Study details: Findings are from a two-sample Mendelian randomization study including patients and matched control individuals for RA (n = 14,361 and n = 43,923, respectively), MI (n = 12,801 and n = 187,840, respectively), IHD (n = 5861 and n = 457,149, respectively), atrial fibrillation (n = 60,620 and n = 970,216, respectively), and arrhythmia (n = 2545 and n = 460,388, respectively).

Disclosures: This study was supported by the Young Talent Development Plan of Changzhou Health Commission, China, and other sources. The authors declared no conflicts of interest.

Source: Wang M et al. Relationship between rheumatoid arthritis and cardiovascular comorbidity, causation or co-occurrence: A Mendelian randomization study. Front Cardiovasc Med. 2023;10:1099861 (Mar 17). Doi: 10.3389/fcvm.2023.1099861

Recommended Reading

Registry data ‘reassure’ on biologics’ heart attack risk in rheumatoid arthritis
MDedge Rheumatology
Meta-analysis examines cancer risk concern for JAK inhibitors
MDedge Rheumatology
Patients with preexisting RA can safely initiate immune checkpoint inhibitors for cancer
MDedge Rheumatology
Discontinuing half-dose csDMARD feasible in some patients with RA in remission
MDedge Rheumatology
Tofacitinib associated with reduced risk of developing ILD in patients with RA
MDedge Rheumatology
RA onset after initiating bDMARD raises risk for severe infections
MDedge Rheumatology
Factors to guide individualized benefit-risk assessment and decision-making with tofacitinib in RA
MDedge Rheumatology
Meta-analysis reveals superior efficacy and safety outcomes with abatacept in RA
MDedge Rheumatology
RA raises risk for bronchial asthma and asthma-related comorbidities
MDedge Rheumatology
Mortality risk accrues with time after diagnosis of RA
MDedge Rheumatology